NGOs protest Novartis' Glivec patent quest in India

Several NGOs protested Thursday at the annual meeting of Novartis against the attempt by the Swiss pharmaceutical group's India company to obtain a patent for its anti-cancer drug Glivec.

The NGOs said that Novartis' action threatens access to in poor countries.

The Berne Declaration, Act Up and Oxfam asked Novartis annual management and shareholders meeting in Basel "to abandon its legal action in India for obtaining a Glivec patent."

"We are asking Novartis once and for all to stop this legal battle in India that is a direct attack on the pharmacy of the developing world," Unni Karunakara, MSF's international president said in a letter to Novartis.

"We will not stand by silently and watch our source of affordable medicines dry up in the future -- we rely on these drugs to do our work in more than 60 countries today."

Forty activists gathered outside the Novartis building, erecting a booth and hoisting banners denouncing Novartis' position.

Glivec generated sales of $4.7 billion (3.5 billion euros) in 2011 and is used in the treatment of (blood and bone marrow cancer) as well as against .

In applying for a patent, "access to cheap medicines would be threatened for the poor in developing countries and and India is one of the main suppliers of generic drugs in the world," said Swiss NGO Berne Declaration in a statement.

According to Oxfam, "the price of Novartis' Glivec is 10 times higher than the cost of generic equivalents."

Novartis filed in 2006 a for Glivec in India.

Indian courts rejected the request this year, saying the drug was a new formulation of an existing product.

The Swiss company has appealed to the Supreme Court of India, which has pushed from February to mid-March its hearing on the case, Patrick Durisch, an activist from the Berne Declaration told AFP.

Novartis, contacted by AFP, was not immediately available for comment.

add to favorites email to friend print save as pdf

Related Stories

Novartis fights patent rejection in Indian court

Sep 06, 2011

(AP) -- In a case that could affect India's role as drug provider to the developing world, the Supreme Court began hearing arguments Tuesday over whether the government had the right to deny a patent to Swiss drugmaker Novartis ...

Novartis announces 2,000 job losses, profits up

Oct 25, 2011

Swiss pharmaceutical giant Novartis announced 2,000 job losses Tuesday, mostly in Switzerland and the United States, while reporting net profits of $3.53 billion (2.5 billion euros) for the third quarter.

Swiss pharma giant Novartis recalls drugs in US

Jan 08, 2012

Swiss pharmaceutical firm Novartis said Sunday it was recalling four different products sold over the counter in the United States over reports of a malfunction at one of its plants.

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

User comments